BM-MSC delivery through IV route has no effect in colitis prevention. (A) Cartoon depicts the experimental schemes for results depicted in panels B-E. Mice (N = 5 per test group) received 4.0% (w/v) of DSS orally for 6 days. BM-MSCs were transferred IP, SC, or IV into the syngeneic mice at days 2 and 4. The development of colitis is examined by measuring body weight change relative to the initial body weight at day 0 (B), disease activity index (C), H&E staining (D), and histological score (E). Bars represent the mean ± SEM (N = 5 for all experiments). (D) Bars represent 100 μm. Statistical analysis was assessed by Student t test (E) and 2-way ANOVA (Tukey test) (B-C). **P < .01, ***P < .001, ****P < .0001.